Last reviewed · How we verify

NCT07402317

Trimodality Bladder Preservation

Completed NA Last updated 11 February 2026
What this trial tests

NA trial testing Transurethral resection of bladder tumor: We are aimed at Complete TURBT. Which was defined as no residual tumor, whereas incomplete TURBT in Bladder Cancer Treatment in 97 participants. Completed in 25 January 2023.

Timeline
11 December 2018
Primary endpoint
1 September 2022
25 January 2023

Quick facts

Lead sponsorAl-Azhar University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment97
Start date11 December 2018
Primary completion1 September 2022
Estimated completion25 January 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Al-Azhar University

Who can join

Adults 18 to 80, any sex, with Bladder Cancer Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is To evaluate the outcomes of patients with muscle invasive bladder cancer managed by trimodal therapy", Neoadjuvant chemotherapy( NAC) followed by Transurethral resection of the bladder tumor then Radiotherapy, for bladder preservation and capability to reach the goal of better quality of life, compared to radical cystectomy with assessment of factors that may predict treatment response, risk of recurrences and (disease- free and over all)survival of such patients...

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Al-Azhar University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07402317.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing